Sunshine Heart Inc was incorporated in Delaware on August 22, 2002. The company is an early-stage medical device company engaged in developing, manufacturing and commercializing its C-Pulse Heart Assist System for treatment of Class III and ambulatory Class IV heart failure. Its C-Pulse Heart Assist System utilizes the scientific principles of intra-aortic balloon counter-pulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. It is in the process of obtaining regulatory approvals necessary to sell its product. Combined, these potential benefits may help reverse the heart failure process or maintain the patient's current condition, thereby potentially preventing the need for later-stage heart failure devices, such as LVADs, artificial hearts or transplants. Its competitors include: AbioMed, Inc., Berlin Heart GmbH, CardioKinetix, Inc., CircuLite, Inc. & HeartWare International Inc. Its business is subject to extensive federal and state government regulation.
Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content.